The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial
Phase 4
- Conditions
- IgA nephropathy
- Registration Number
- JPRN-C000000380
- Lead Sponsor
- ARB therapeutic society of IgA nephropathy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1)patients with nephrotic syndorome. 2)patients who administered steroid or discontinuted within 6 months prior to enrolment in the study. 3)patients with serious liver dysfunction. 4)pregnant women or women of child bearing potential and nursing women. 5)patients with hypersensitivity to angiotensin II receptor blocker and angiotensin convertig enzyme inhibitor. 6)Other patients who are judged to be inappropriate for the study by the investigator or subinvestigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method